JP2023518640A5 - - Google Patents
Info
- Publication number
- JP2023518640A5 JP2023518640A5 JP2022542038A JP2022542038A JP2023518640A5 JP 2023518640 A5 JP2023518640 A5 JP 2023518640A5 JP 2022542038 A JP2022542038 A JP 2022542038A JP 2022542038 A JP2022542038 A JP 2022542038A JP 2023518640 A5 JP2023518640 A5 JP 2023518640A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- integer
- diseases
- pathologies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES202030070A ES2846824B2 (es) | 2020-01-29 | 2020-01-29 | Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos |
| ESP202030070 | 2020-01-29 | ||
| EP20382145.9 | 2020-02-28 | ||
| EP20382145 | 2020-02-28 | ||
| ES202031155A ES2911474B2 (es) | 2020-11-17 | 2020-11-17 | Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores |
| ESP202031155 | 2020-11-17 | ||
| PCT/ES2021/070068 WO2021152201A2 (es) | 2020-01-29 | 2021-01-28 | Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518640A JP2023518640A (ja) | 2023-05-08 |
| JP2023518640A5 true JP2023518640A5 (enExample) | 2024-02-05 |
| JP7736313B2 JP7736313B2 (ja) | 2025-09-09 |
Family
ID=77078835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542038A Active JP7736313B2 (ja) | 2020-01-29 | 2021-01-28 | αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230097753A1 (enExample) |
| EP (1) | EP4098649A4 (enExample) |
| JP (1) | JP7736313B2 (enExample) |
| KR (1) | KR20220132552A (enExample) |
| CN (1) | CN115052852A (enExample) |
| AU (2) | AU2021212330A1 (enExample) |
| BR (1) | BR112022015172A2 (enExample) |
| CA (2) | CA3233141A1 (enExample) |
| CL (1) | CL2022001985A1 (enExample) |
| IL (1) | IL295120A (enExample) |
| MX (1) | MX2022009035A (enExample) |
| WO (1) | WO2021152201A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| ES2982396A1 (es) * | 2023-03-14 | 2024-10-15 | Veritas Therapeutics S L | 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1147221B (de) * | 1958-06-28 | 1963-04-18 | Dr Rer Nat Gernot Grimmer | Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der Pentadecen- und Heptadecensaeuren |
| DE1195296B (de) * | 1958-06-28 | 1965-06-24 | Dr Gernot Grimmer | Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure |
| GB1156465A (en) * | 1967-02-16 | 1969-06-25 | Unilever Ltd | Prostaglandins |
| US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB9926833D0 (en) * | 1999-11-15 | 2000-01-12 | Univ Sunderland | Compositions |
| DE102007055344A1 (de) * | 2007-11-19 | 2009-05-20 | K. D. Pharma Bexbach Gmbh | Neue Verwendung von Omega-3-Fettsäure(n) |
| ES2342997B1 (es) * | 2008-12-09 | 2011-06-06 | Universitat De Les Illes Balears | Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento. |
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| CA2763041C (en) * | 2009-05-29 | 2018-11-27 | Robert A. Newman | Compositions and methods for modulating lipid composition |
| CN102276444B (zh) * | 2011-05-04 | 2013-10-09 | 厦门大学 | 脂肪酸类化合物及其制备方法与应用 |
| ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
| WO2014113584A1 (en) * | 2013-01-16 | 2014-07-24 | Rhode Island Hospital | Compositions and methods for the prevention and treatment of osteolysis and osteoporosis |
| US20150173410A1 (en) * | 2013-12-19 | 2015-06-25 | Change Cola, Inc. | Beverage comprising omega fatty acid |
| JP2016222590A (ja) * | 2015-05-29 | 2016-12-28 | 国立大学法人東京海洋大学 | 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬 |
| CN112996500A (zh) * | 2018-06-15 | 2021-06-18 | 优美佳生物技术有限公司 | 用于调节elovl2的组合物和方法 |
-
2021
- 2021-01-28 WO PCT/ES2021/070068 patent/WO2021152201A2/es not_active Ceased
- 2021-01-28 AU AU2021212330A patent/AU2021212330A1/en not_active Abandoned
- 2021-01-28 EP EP21748005.2A patent/EP4098649A4/en active Pending
- 2021-01-28 CN CN202180011594.4A patent/CN115052852A/zh active Pending
- 2021-01-28 MX MX2022009035A patent/MX2022009035A/es unknown
- 2021-01-28 IL IL295120A patent/IL295120A/en unknown
- 2021-01-28 CA CA3233141A patent/CA3233141A1/en active Pending
- 2021-01-28 CA CA3166307A patent/CA3166307C/en active Active
- 2021-01-28 BR BR112022015172A patent/BR112022015172A2/pt unknown
- 2021-01-28 US US17/759,782 patent/US20230097753A1/en active Pending
- 2021-01-28 JP JP2022542038A patent/JP7736313B2/ja active Active
- 2021-01-28 KR KR1020227027634A patent/KR20220132552A/ko active Pending
-
2022
- 2022-07-21 CL CL2022001985A patent/CL2022001985A1/es unknown
-
2023
- 2023-10-13 AU AU2023248158A patent/AU2023248158B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3908570B1 (en) | Ketamine pamoate and use thereof | |
| JP2026035701A5 (enExample) | ||
| KR20160093000A (ko) | 창자 과투과성을 치료하기 위한 티로신 하이드록실라제 억제제 | |
| JP7051133B2 (ja) | 口内乾燥症（ｘｅｒｏｓｔｏｍｉａ）の治療のための組成物および方法 | |
| JP2013509411A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2023518640A5 (enExample) | ||
| JP2020100623A (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
| CN107835695A (zh) | 用于治疗自闭症的组合物和方法 | |
| JP2021530543A5 (enExample) | ||
| JP2023553253A5 (enExample) | ||
| CN109310669B (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| WO2012052918A1 (en) | Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome | |
| JP7417595B2 (ja) | てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| TWI555528B (zh) | 泛醇基二十二碳六烯酸酯及其於治療與預防心血管疾病的用途 | |
| JP2022518288A5 (enExample) | ||
| CN104177318A (zh) | L-抗坏血酸-6-（10-羟基-2-癸烯酸）酯或其衍生物以及它们的应用 | |
| JPH0813741B2 (ja) | 抗痴呆剤 | |
| JPH0840902A (ja) | 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物 | |
| JP2024522820A5 (enExample) | ||
| JP2024526939A5 (enExample) | ||
| CN106946866A (zh) | 一种预防和治疗脑卒中的药物及其制备方法 | |
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| CA3118954C (en) | Ketamine pamoate and use thereof | |
| RU2825336C2 (ru) | Кетамин памоат и его применение |